Researchers have developed a new genetic test that can determine whether breast cancer patients can avoid chemotherapy. Putting the test to work, researchers found that most women with early-stage breast cancer may be able to skip the treatment, although the same does not necessarily apply to those who have larger tumors or those with cancer that has started to spread. Of the more than 250,000 women in the US expected to be diagnosed with breast cancer, the new findings could benefit more than 63,000 with non-invasive, or early stage breast cancer.